Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22945216 | 0.82 | PDE4B (0.49) | F11MGLLGPR183ALDH1A1SCD5 | |
| SCHEMBL23981839 | 0.81 | PDE4B (0.49) | F11MGLLGPR183KCNH2HDAC4 | |
| SCHEMBL21425080 | 0.81 | F11 (0.53) | F11MGLLGPR183KCNH2HDAC4 | |
| SCHEMBL23009605 | 0.81 | F11 (0.53) | F11MGLLGPR183KCNH2HDAC4 | |
| SCHEMBL23009728 | 0.80 | F11 (0.59) | F11MGLLGPR183KCNH2HDAC4 | |
| SCHEMBL23009606 | 0.78 | F11 (0.59) | F11MGLLGPR183KCNH2HDAC4 | |
| SCHEMBL21425180 | 0.76 | HRH3 (0.46) | ALDH1A1PROKR1 | |
| SCHEMBL21425235 | 0.74 | PROKR1 (0.53) | ALDH1A1PROKR1SMN1; SMN2 | |
| SCHEMBL29575189 | 0.73 | HDAC4 (0.48) | F11MGLLGPR183HDAC4RECQL | |
| SCHEMBL18828501 | 0.73 | HDAC4 (0.48) | F11MGLLGPR183HDAC4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| EP-3778588-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | F2, PCSK9, F9 | F11 15/4885MGLL 2528/4885GPR183 3932/4885 |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | F2, PCSK9, F9 | F11 15/4885MGLL 2528/4885GPR183 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.